Morning Buzz: Achillion (ACHN), Regulus (RGLS), Compugen (CGEN), Apple (AAPL)

Shares of Achillion Pharmaceuticals, Inc. (ACHN) gained nearly 14% to $12.32 in Monday’s pre-market trading session, after the company announced positive Phase 2 ACH-3102 data. “The ability to further shorten treatment duration to only six weeks and maintain excellent SVR12 rates remains the goal for clinicians and patients, and I am pleased that these Phase […] View the full post at: Morning Buzz: Achillion (ACHN), Regulus (RGLS), Compugen (CGEN), Apple (AAPL) Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock